Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2(V617F)-myeloproliferative neoplasm

A 62-year-old woman, who had a 16-year history of JAK2(V617F)-mutated myeloproliferative neoplasm (MPN), developed Burkitt leukemia (BL) 16 months after treatment with ruxolitinib to control hydroxyurea-refractory conditions. BL cells were CD10(+), CD19(+), CD20(−), CD34(−), cytoplasmic CD79a(+), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukutsuka, Katsuhiro, Iioka, Futoshi, Maekawa, Fumiyo, Nakagawa, Miho, Kishimori, Chiyuki, Hayashida, Masahiko, Tagawa, Shunsuke, Akasaka, Takashi, Honjo, Gen, Ohno, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265492/
https://www.ncbi.nlm.nih.gov/pubmed/33994432
http://dx.doi.org/10.3960/jslrt.21001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265492/
https://www.ncbi.nlm.nih.gov/pubmed/33994432
http://dx.doi.org/10.3960/jslrt.21001

Ejemplares similares